Prelude Therapeutics Inc (PRLD) — SEC Financial Statements & Analysis

Prelude Therapeutics Inc (PRLD) is a pharmaceutical preparations company, incorporated in DE. Prelude Therapeutics Inc trades on Nasdaq as: PRLD. Prelude Therapeutics Inc (PRLD)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-11. Based on that filing, Prelude Therapeutics Inc carries a market cap of $524.41M, a P/E ratio of -8.67x, a P/B ratio of 3.92x, a P/S ratio of 23.39x, an enterprise value of $498.08M, and an EV/EBITDA multiple of -7.57x. On profitability, it posts an operating margin of -300.56%, a net margin of -269.75%, a Return on Equity (ROE) of -57.73%, a Return on Assets (ROA) of -39.76%, and a Return on Invested Capital (ROIC) of -85.27%. Per share, it reports EPS of $-0.61, diluted EPS of $-0.61, free cash flow per share of $-0.34, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of 220.34% year-over-year, net income growth of -51.34% year-over-year, and EPS growth of -62.42% year-over-year. On the balance sheet, it maintains a current ratio of 4.07x, a quick ratio of 3.99x, working capital of $116.86M, a debt-to-equity ratio of 0.42x, a debt ratio of 0.29, free cash flow of $-33.26M (TTM), and net debt of $-26.33M. Figures sourced from SEC EDGAR.

Market Cap

$524.41M

P/E TTM

-8.67x

EPS TTM

$-0.61

P/B TTM

3.92x

ROE TTM

-57.73%

ROA TTM

-39.76%

Debt To Equity

0.42x

Free Cash Flow TTM

$-33.26M

Net Revenue TTM Growth 1Y

220.34%

Data as of 2026-06-30 · Source: SEC EDGAR